BioCentury | Mar 28, 2016
Finance

Back in the game

After spending the last few years exiting many of its biotech portfolio companies, Gimv is again putting capital to work in the space. The firm is picking up where it left off with a bet...
BioCentury | Oct 19, 2015
Finance

Funding cycles

After five years of drip feeding Bicycle Therapeutics Ltd. , the investor syndicate has installed new CEO Kevin Lee into a company that's fully funded to advance programs into the clinic. The VCs think the measured...
BC Extra | Mar 11, 2015
Company News

Management tracks

Oncology play Bind Therapeutics Inc. (NASDAQ:BIND) named Andrew Hirsch as acting president and CEO. Hirsch, formerly Bind's COO and CFO, replaces Scott Minick, who will remain on Bind's board. The company also appointed Dan Koerwer...
BioCentury | Sep 22, 2014
Product Development

Glenmark's new cancer BEAT

While bispecific antibodies have been around for two decades, their success in cancer has been stymied by poor in vivo properties and complex manufacturing processes. Indian biotech Glenmark Pharmaceuticals Ltd. is making a play in...
BC Week In Review | Sep 1, 2014
Company News

Covagen, J&J deal

Johnson & Johnson’s Cilag GmbH International subsidiary acquired mAb platform company Covagen for an undisclosed amount. Covagen is developing a pipeline of products using its FynomAb engineering technology, which fuses antibodies to Fynomers. Fynomers are...
BioCentury | Sep 1, 2014
Finance

Exiting Covagen

Terms of Johnson & Johnson 's takeout of Covagen AG are undisclosed, but the antibody platform company's largest investor said the deal is likely one of the biggest this year in terms of both size...
BC Extra | Aug 26, 2014
Company News

J&J acquires antibody play Covagen

The Cilag GmbH International subsidiary of Johnson & Johnson (NYSE:JNJ) acquired mAb platform company Covagen AG (Zurich, Switzerland) for an undisclosed amount. Covagen is developing a pipeline of products using its FynomAb engineering technology, which...
BC Week In Review | May 12, 2014
Clinical News

COVA322: Phase Ib/IIa started

Covagen began a double-blind, placebo-controlled, German Phase Ib/IIa trial to evaluate single ascending-doses of COVA322 in about 39 patients with psoriasis. COVA322 was developed using Covagen's Fynomer protein engineering technology. Fynomers are based on the...
BC Week In Review | Feb 24, 2014
Financial News

Covagen financial update

The company raised an undisclosed amount from new investor Baxter Ventures in the second close of a CHF44.9 million ($50.3 million) series B round. Covagen did not disclose the amounts invested by individual parties. In...
BC Week In Review | Dec 16, 2013
Financial News

Covagen completes venture financing

Covagen AG , Zurich, Switzerland   Business: Inflammation, Cancer, Autoimmune   Date completed: 12/9/13   Type: Venture financing   Raised: Not disclosed   Investors: Gimv; Ascent Biomedical Ventures; Novartis Venture Funds; Edmond de Rothschild Investment Partners;...
Items per page:
1 - 10 of 26
BioCentury | Mar 28, 2016
Finance

Back in the game

After spending the last few years exiting many of its biotech portfolio companies, Gimv is again putting capital to work in the space. The firm is picking up where it left off with a bet...
BioCentury | Oct 19, 2015
Finance

Funding cycles

After five years of drip feeding Bicycle Therapeutics Ltd. , the investor syndicate has installed new CEO Kevin Lee into a company that's fully funded to advance programs into the clinic. The VCs think the measured...
BC Extra | Mar 11, 2015
Company News

Management tracks

Oncology play Bind Therapeutics Inc. (NASDAQ:BIND) named Andrew Hirsch as acting president and CEO. Hirsch, formerly Bind's COO and CFO, replaces Scott Minick, who will remain on Bind's board. The company also appointed Dan Koerwer...
BioCentury | Sep 22, 2014
Product Development

Glenmark's new cancer BEAT

While bispecific antibodies have been around for two decades, their success in cancer has been stymied by poor in vivo properties and complex manufacturing processes. Indian biotech Glenmark Pharmaceuticals Ltd. is making a play in...
BC Week In Review | Sep 1, 2014
Company News

Covagen, J&J deal

Johnson & Johnson’s Cilag GmbH International subsidiary acquired mAb platform company Covagen for an undisclosed amount. Covagen is developing a pipeline of products using its FynomAb engineering technology, which fuses antibodies to Fynomers. Fynomers are...
BioCentury | Sep 1, 2014
Finance

Exiting Covagen

Terms of Johnson & Johnson 's takeout of Covagen AG are undisclosed, but the antibody platform company's largest investor said the deal is likely one of the biggest this year in terms of both size...
BC Extra | Aug 26, 2014
Company News

J&J acquires antibody play Covagen

The Cilag GmbH International subsidiary of Johnson & Johnson (NYSE:JNJ) acquired mAb platform company Covagen AG (Zurich, Switzerland) for an undisclosed amount. Covagen is developing a pipeline of products using its FynomAb engineering technology, which...
BC Week In Review | May 12, 2014
Clinical News

COVA322: Phase Ib/IIa started

Covagen began a double-blind, placebo-controlled, German Phase Ib/IIa trial to evaluate single ascending-doses of COVA322 in about 39 patients with psoriasis. COVA322 was developed using Covagen's Fynomer protein engineering technology. Fynomers are based on the...
BC Week In Review | Feb 24, 2014
Financial News

Covagen financial update

The company raised an undisclosed amount from new investor Baxter Ventures in the second close of a CHF44.9 million ($50.3 million) series B round. Covagen did not disclose the amounts invested by individual parties. In...
BC Week In Review | Dec 16, 2013
Financial News

Covagen completes venture financing

Covagen AG , Zurich, Switzerland   Business: Inflammation, Cancer, Autoimmune   Date completed: 12/9/13   Type: Venture financing   Raised: Not disclosed   Investors: Gimv; Ascent Biomedical Ventures; Novartis Venture Funds; Edmond de Rothschild Investment Partners;...
Items per page:
1 - 10 of 26